Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Germany

Research and Innovation Action · Running

MUNASET Multiparametric nanoelectronic biosensors for therapy response testing

Coordinator
Hochschule Kaiserslautern, Germany
Runs
1 October 2023 to 31 March 2028
Status
Running
EU funding
€4.0m
Total cost
€4.0m
Partners
6 organisations in 4 countries
Type
Research and Innovation Action
Grant agreement
101119473

What the project is doing

In the project's own words, from its summary on CORDIS.

Proteases recently emerged as a promising new class of biomarkers with a broad diagnostic, prognostic and therapeutic potential for different human diseases including neurological and psychiatric diseases, several types of cancer, and immune system disorders. However, there is a lack of tools for real-time activity analysis of disease-related protease biomarkers. To address this issue, we propose to develop a highly sensitive graphene-based biosensor platform for parallel detection of multiple proteases in serum.

We will exploit a new label-free sensing mechanism based on charge removal due to cleavage of designer peptides by proteases. As a specific business case, we plan to address therapy response prediction along treatment of major depressive disorder (MDD). MDD is one of the most common and burdensome mental disorders worldwide. MDD is also among the most expensive brain diseases in Europe. While effective treatments exist, there is a high variability in treatment response.

There are no serum-based tests to predict personalized therapy for MDD patients. The effective treatment is identified through trial and error, a great burden for patients and the health care system. A rapid, sensitive and easy-to-use test would allow faster and more precise treatment identification, improving therapy outcomes and reducing hospitalization times. Here, we plan to detect two protease biomarkers associated with MDD.

The biosensors will be validated in clinical serum samples. Arrays of graphene biosensors will be integrated on silicon wafers with a multiplexed readout matrix to realize a miniaturized sensor system with multi-analyte detection capability, high dynamic range, high precision, low detection limit, and low material consumption. The resulting platform technology may enable various point-of-care diagnostic and therapy prediction tools.

This will help secure industrial leadership of the EU over the entire value chain of novel graphene-based bio-analytical tools.

Who is involved

OrganisationCityCountryRole
Hochschule KaiserslauternKaiserslauternGermanyCoordinator
Pro-ActiveWaterlooBelgiumParticipant
Johannes Gutenberg-Universitat MainzMainzGermanyParticipant
Universitaetsmedizin Der Johannes Gutenberg-Universitaet MainzMainzGermanyParticipant
Graphenea Semiconductor SLDonostiaSpainParticipant
Teknologian Tutkimuskeskus VTT OyEspooFinlandParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI